<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126125">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987674</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr2013/239-31PMB</org_study_id>
    <nct_id>NCT01987674</nct_id>
  </id_info>
  <brief_title>Pre-meal Protein Drink Improve Glycemic Regulation</brief_title>
  <acronym>PMB/T2D</acronym>
  <official_title>Impact of a Pre-meal Protein Drink on Metabolic Markers and Glycemic Control in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Landstinget i Kalmar Län</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if a pre-meal drink containing proteins can
      positively influence glycaemic control in patients with type 2 diabetes mellitus. Comparison
      with a placebo is included.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Glycated hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycemia</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Meal challenge given at start and end of study with repeated blood glucose sampling over 2h.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Homeostasis model assessment of insulin resistance (HOMA-IR)</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HOMA-IR is a mathematical modelling of insulin resistance using fasting values of blood glucose and serum insulin.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pre-meal protein drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 100 ml is taken just before breakfast, lunch and dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A dose of 100 ml is taken just before breakfast, lunch and dinner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pre-meal protein drink</intervention_name>
    <arm_group_label>Pre-meal protein drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water drink</intervention_name>
    <arm_group_label>Water drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed type 2 diabetes mellitus according to WHO criteria (1999)

          -  age between 30-80 years

          -  non well controlled diabetes with HbA1c-levels above 62 mmol/mol

        Exclusion Criteria:

          -  pregnant or risk of becoming pregnant

          -  severe disease

          -  psychological disease, dementia or mental disability that makes it impossible to
             retrieve informed consent of participation

          -  liver disease

          -  kidney malfunction (GFR &lt;60 or aspartate transaminase (ASAT)/alanine transaminase
             (ALT) two times higher than the normal interval
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lindsdals hälsocentral</name>
      <address>
        <city>Kalmar</city>
        <zip>39365</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Elin Östman</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
